Annual report
4208.TEDINET S100YD42
Period2025-04-01 → 2026-03-31
Filed2026-06-18
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 156
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥462.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥486.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥468.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥494.7bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥655.3bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥18.9bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥18.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥37.5bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥22.4bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥36.3bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥8.7bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥41.5bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥30.7bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥10.9bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥23.9bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥4.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.0bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥7.0bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥24.5bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥24.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | −¥9.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥946.3bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥866.2bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥789.0bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥732.7bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥838.0bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥491.4bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥453.9bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥454.9bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥412.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥429.4bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥381.6bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥394.0bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥55.8bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥116.0bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥52.6bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥115.4bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥35.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥30.7bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥78.8bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥60.0bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥35.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥53.0bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥18.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥32.7bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥140.2bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥63.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥33.3bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥26.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥43.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥13.0bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥105.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥15.7bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥8.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥245.76 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-49.6 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥298.59 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-72.54 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥249.31 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥245.73 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥298.45 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥248.56 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥4,500.48 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,067.9 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,210.11 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,726.39 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,813.16 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 46.2% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.8% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.4% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.1% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.7% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | -1.2% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | -1.9% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.7% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 7,968 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 7,563 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 7,882 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 8,028 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 9,849 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥154.8bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥162.1bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥164.0bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥182.4bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥274.8bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥3.1bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥1.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥25.2bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥22.4bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥20.5bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥23.7bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥28.1bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥24.1bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥5.7bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥22.2bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥9.7bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥16.5bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.1bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥21.4bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥607.3bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥637.1bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥463.6bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥450.6bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥485.4bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥391.0bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥434.1bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥216.3bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥202.9bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥203.2bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥193.8bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥184.1bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥9.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥61.0bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥228.56 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥100.4 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥170.08 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥197.04 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥217.38 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥228.53 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥100.36 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥170 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥196.82 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥216.72 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥110 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥110 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥105 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥95 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥95 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,226.28 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,089.11 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,092.43 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,996.63 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,896.64 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 35.6% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.8% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.0% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.8% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 10.6% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.3% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.1% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.6% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 106,200,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 106,200,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 106,200,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 106,200,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 106,200,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,778 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 2,693 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 2,243 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 2,216 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 2,058 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 120
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2026-03-31 | 1112 pure |
| Otherother segments | capex | 2025-04-01 → 2026-03-31 | ¥1.2bn |
| Otherother segments | depreciation | 2025-04-01 → 2026-03-31 | ¥1.7bn |
| Otherother segments | revenue | 2025-04-01 → 2026-03-31 | ¥34.5bn |
| Otherother segments | revenue external | 2025-04-01 → 2026-03-31 | ¥48.1bn |
| Otherother segments | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥13.7bn |
| Otherother segments | segment assets | at 2026-03-31 | ¥52.4bn |
| Otherother segments | segment profit | 2025-04-01 → 2026-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥4.4bn |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥3.2bn |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥21.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥21.2bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥235.6bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥5.4bn |
| High Performance Urethansreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥4.1bn |
| High Performance Urethansreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥3.4bn |
| High Performance Urethansreportable segment | employees | at 2026-03-31 | 496 pure |
| High Performance Urethansreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥46.5bn |
| High Performance Urethansreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥46.1bn |
| High Performance Urethansreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥419m |
| High Performance Urethansreportable segment | segment assets | at 2026-03-31 | ¥129.1bn |
| High Performance Urethansreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥548m |
| Machineryreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥3.3bn |
| Machineryreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥1.7bn |
| Machineryreportable segment | employees | at 2026-03-31 | 1572 pure |
| Machineryreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥68.4bn |
| Machineryreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥68.1bn |
| Machineryreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥327m |
| Machineryreportable segment | segment assets | at 2026-03-31 | ¥78.1bn |
| Machineryreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥6.2bn |
| Pharmaceuticalreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥3.9bn |
| Pharmaceuticalreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥2.5bn |
| Pharmaceuticalreportable segment | employees | at 2026-03-31 | 521 pure |
| Pharmaceuticalreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥21.0bn |
| Pharmaceuticalreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥20.6bn |
| Pharmaceuticalreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥364m |
| Pharmaceuticalreportable segment | segment assets | at 2026-03-31 | ¥41.1bn |
| Pharmaceuticalreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥1.3bn |
| Polymers And Chemicalsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥40.4bn |
| Polymers And Chemicalsreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥8.6bn |
| Polymers And Chemicalsreportable segment | employees | at 2026-03-31 | 1662 pure |
| Polymers And Chemicalsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥251.2bn |
| Polymers And Chemicalsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥228.4bn |
| Polymers And Chemicalsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥22.8bn |
| Polymers And Chemicalsreportable segment | segment assets | at 2026-03-31 | ¥307.2bn |
| Polymers And Chemicalsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥8.2bn |
| Specialty Productsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥11.6bn |
| Specialty Productsreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥4.6bn |
| Specialty Productsreportable segment | employees | at 2026-03-31 | 610 pure |
| Specialty Productsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥61.9bn |
| Specialty Productsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥50.9bn |
| Specialty Productsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥11.0bn |
| Specialty Productsreportable segment | segment assets | at 2026-03-31 | ¥102.8bn |
| Specialty Productsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥9.8bn |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥64.6bn |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥22.5bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥483.6bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥462.3bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥21.2bn |
| —segment total | segment assets | at 2026-03-31 | ¥710.7bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥24.3bn |
| Otherother segments | capex | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Otherother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Otherother segments | revenue | 2024-04-01 → 2025-03-31 | ¥39.2bn |
| Otherother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥50.1bn |
| Otherother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥10.9bn |
| Otherother segments | segment assets | at 2025-03-31 | ¥52.8bn |
| Otherother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥2.1bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥5.4bn |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥2.8bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥26.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥26.1bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥235.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥3.8bn |
| High Performance Urethansreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥582m |
| High Performance Urethansreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥838m |
| High Performance Urethansreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥15.6bn |
| High Performance Urethansreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥15.1bn |
| High Performance Urethansreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥549m |
| High Performance Urethansreportable segment | segment assets | at 2025-03-31 | ¥98.7bn |
| High Performance Urethansreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥200m |
| Machineryreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥2.9bn |
| Machineryreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| Machineryreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥86.9bn |
| Machineryreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥86.4bn |
| Machineryreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥514m |
| Machineryreportable segment | segment assets | at 2025-03-31 | ¥79.0bn |
| Machineryreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥7.9bn |
| Pharmaceuticalreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥2.8bn |
| Pharmaceuticalreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| Pharmaceuticalreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥31.5bn |
| Pharmaceuticalreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥29.8bn |
| Pharmaceuticalreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Pharmaceuticalreportable segment | segment assets | at 2025-03-31 | ¥39.9bn |
| Pharmaceuticalreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Polymers And Chemicalsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥33.5bn |
| Polymers And Chemicalsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥13.5bn |
| Polymers And Chemicalsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥273.6bn |
| Polymers And Chemicalsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥255.2bn |
| Polymers And Chemicalsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥18.3bn |
| Polymers And Chemicalsreportable segment | segment assets | at 2025-03-31 | ¥265.9bn |
| Polymers And Chemicalsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥713m |
| Specialty Productsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥14.2bn |
| Specialty Productsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥4.1bn |
| Specialty Productsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥66.2bn |
| Specialty Productsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥50.3bn |
| Specialty Productsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥15.9bn |
| Specialty Productsreportable segment | segment assets | at 2025-03-31 | ¥94.0bn |
| Specialty Productsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥11.7bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥55.3bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥24.4bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥512.9bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥486.8bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥26.1bn |
| —segment total | segment assets | at 2025-03-31 | ¥630.3bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥21.8bn |
| High Performance Urethansreportable segment | employees | at 2026-03-31 | 19 pure |
| Pharmaceuticalreportable segment | employees | at 2026-03-31 | 517 pure |
| Polymers And Chemicalsreportable segment | employees | at 2026-03-31 | 80 pure |
| Specialty Productsreportable segment | employees | at 2026-03-31 | 167 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,032
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | 68400 | |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row11Member | 68400 | |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | 239000000 | JPY |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row11Member | 198000000 | JPY |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | 100000 | |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row12Member | 100000 | |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | 77000000 | JPY |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row12Member | 71000000 | JPY |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | － | |
| Number of shares held details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row13Member | 43700 | |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row13Member | － | JPY |
| Book value details of specified investment equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row13Member | 198000000 | JPY |
| Number of shares held details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | 4000000 | |
| Number of shares held details of deemed holdings of equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row1Member | 4000000 | |
| Book value details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | 9626000000 | JPY |
| Book value details of deemed holdings of equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row1Member | 7028000000 | JPY |
| Number of shares held details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | 565500 | |
| Number of shares held details of deemed holdings of equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row2Member | 565500 | |
| Book value details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | 1470000000 | JPY |
| Book value details of deemed holdings of equity securities held for purposes other than pure investment reporting company | Prior1YearInstant_Row2Member | 1137000000 | JPY |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E01002-000SpecialtyProductsReportableSegmentsMember | 610 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E01002-000HighPerformanceUrethansReportableSegmentsMember | 496 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E01002-000PharmaceuticalReportableSegmentsMember | 521 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E01002-000PolymersAndChemicalsReportableSegmentsMember | 1662 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E01002-000MachineryReportableSegmentsMember | 1572 | |
| Number of employees | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1112 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 1995 | |
| Number of employees | CurrentYearInstant | 7968 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 2778 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 43.4 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 15.3 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7745921 | JPY |
| Change from previous fiscal year in average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 0.000 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E01002-000SpecialtyProductsReportableSegmentsMember | 167 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E01002-000HighPerformanceUrethansReportableSegmentsMember | 19 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E01002-000PharmaceuticalReportableSegmentsMember | 517 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E01002-000PolymersAndChemicalsReportableSegmentsMember | 80 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 1995 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 2778 | |
| Ratio of female employees in managerial positions metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.065 | |
| All employees calculated based on provisions of article714 item1 of ordinance for enforcement of act on childcare leave caregiver leave and other measures for the welfare of workers caring for children or other family members ratio of male employees taking childcare leave metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.967 | |
| All employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.797 | |
| Regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.795 | |
| Non regular employees differences in wages between male and female employees metrics of reporting company | CurrentYearInstant_NonConsolidatedMember | 0.725 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.020 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.866 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.793 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.823 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.545 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.093 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |